Other CETP Inhibitors Could Escape Torcetrapib Trap, ACC Studies Suggest
The failure of Pfizer's torcetrapib need not be the death knell of the cholesteryl ester transfer protein inhibitor class, according to analysis of imaging studies presented at the American College of Cardiology Scientific Sessions, because there are several plausible reasons that the lack of efficacy could be due to molecule-specific problems
You may also be interested in...
With cheap, proven statins aplenty, cost constraints are “off the table” when it comes to vastly broadening primary prevention, authors of new cholesterol guidelines say at the 2013 AHA meeting. However, evidence for drugs to lower triglycerides and boost HDL is lacking, and focus should be on lifestyle change, they say.
The much anticipated results from Pfizer's failed torcetrapib trials did little to illuminate the cause of adverse outcomes in cholesteryl ester transfer protein inhibition, leaving an expectant industry with a charge to start more clinical trials
Pfizer is hoping to use the results of its failed torcetrapib trials as additional evidence of Lipitor's efficacy in halting progression of atherosclerosis, while competitor AstraZeneca offers new data to expand Crestor's use into early atherosclerosis